Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 54 Results

Title
Intervention Indication Therapeutic Area Year Actions
Paclitaxel with Encequidar for advanced breast cancer Encequidar (HM-30181) , Paclitaxel (Taxol; paclitaxel albumin) Breast cancer Breast Cancer 2022 View  |  Download
Olaparib for BRCA mutated and high risk HER2 negative breast cancer - adjuvant therapy Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Breast cancer Breast Cancer 2020 View  |  Download
Neoadjuvant atezolizumab with chemotherapy followed by adjuvant atezolizumab for treating triple-negative breast cancer Atezolizumab (Tecentriq; MPDL3280A) , Chemotherapy Breast cancer Breast Cancer 2022 View  |  Download
Leuprorelin acetate in addition to tamoxifen or an aromatase inhibitor for ER-positive early stage breast cancer in premenopausal women - adjuvant Leuprorelin acetate (Prostap DCS; Prostap Depot) , Tamoxifen Breast cancer Breast Cancer 2018 View  |  Download
Leuprorelin acetate for the preservation of ovarian function in premenopausal women with neoplastic disease undergoing chemotherapy Leuprorelin acetate (Prostap DCS; Prostap Depot) Ovarian function Breast Cancer , Gynaecology and Obstetrics 2018 View  |  Download
Leuprorelin acetate for advanced breast cancer in pre or perimenopausal women – adjuvant Leuprorelin acetate (Prostap DCS; Prostap Depot) Breast cancer Breast Cancer 2018 View  |  Download
Ipatasertib in addition to paclitaxel for locally advanced or metastatic triple-negative breast cancer Ipatasertib (GDC-0068; RG7440) , Paclitaxel (Taxol; paclitaxel albumin) Breast cancer Breast Cancer 2020 View  |  Download
Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer Fulvestrant (Faslodex) , Inavolisib (GDC 0077;RG 6114) , Palbociclib (Ibrance; PD-0332991) Breast cancer Breast Cancer 2024 View  |  Download
Imlunestrant with or without abemaciclib for treating ER-positive, HER2-negative locally advanced or metastatic breast cancer after endocrine therapy Imlunestrant Breast cancer Breast Cancer 2023 View  |  Download
Giredestrant with palbociclib for previously untreated advanced or metastatic breast cancer Giredestrant , Givosiran (ALN-AS1) , Palbociclib Breast cancer Breast Cancer 2022 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications